Literature DB >> 8072682

Analysis of "pure" congenital muscular dystrophies in thirty-eight cases. How different is the classical type 1 from the occidental type cerebromuscular dystrophy?

H Topaloğlu1, G Kale, D Yalnizoğlu, A H Taşdemir, A Karaduman, M Topçu, E Kotiloğlu.   

Abstract

Congenital muscular dystrophies (CMD) are heterogenous in clinical and pathologic manifestations. The "pure" classical form includes cases without severe impairment of intellectual development (Type 1), and cases with normal or subnormal IQ which show white matter hypodensity on CT scan examination. This latter group is sometimes called the "occidental type cerebro-muscular dystrophy" (OCMD). In this study we report clinical and pathologic findings in 38 cases with pure CMD. Eighteen of them were classified as Type 1 and 20 as OCMD, following the neuroradiological work-up. Statistical analysis between the two groups were done for: age range, consanguinity, multiple joint contractures, maximal motor capacity, facial involvement, high CK, endomysial fibrosis, adiposis, fiber atrophy and necrosis. CK was significantly higher in the OCMD group. Though not statistically significant, multiple joint contractures and muscle fiber necrosis were seen in more OCMD patients. These parameters denoted severity. The results of electrophysiological tests did not show any statistical differences. In pure CMDs there is evidence for overlap between the two sub-groups. OCMD cases may tend to run a more severe course in the presence of significantly higher CK levels.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8072682     DOI: 10.1055/s-2008-1071593

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  1 in total

1.  A cross section of autosomal recessive limb-girdle muscular dystrophies in 38 families.

Authors:  P Dinçer; Z Akçören; E Demir; I Richard; O Sancak; G Kale; S Ozme; A Karaduman; E Tan; J A Urtizberea; J S Beckmann; H Topaloğlu
Journal:  J Med Genet       Date:  2000-05       Impact factor: 6.318

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.